MiNK Therapeutics (NASDAQ:INKT) Trading Down 1.8% – Should You Sell?

MiNK Therapeutics, Inc. (NASDAQ:INKT)’s stock price was down 1.8% on Wednesday . The company traded as low as $0.64 and last traded at $0.65. Approximately 25,556 shares were traded during mid-day trading, a decline of 70% from the average daily volume of 86,186 shares. The stock had previously closed at $0.66.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on INKT shares. HC Wainwright restated a “buy” rating and issued a $9.00 price target on shares of MiNK Therapeutics in a report on Friday, November 15th. Robert W. Baird lowered their price target on shares of MiNK Therapeutics from $8.00 to $4.00 and set an “outperform” rating on the stock in a report on Friday, November 15th.

MiNK Therapeutics Trading Down 2.2 %

The stock has a market capitalization of $24.36 million, a PE ratio of -1.58 and a beta of 0.10. The company’s 50-day moving average is $0.71 and its 200 day moving average is $0.81.

Hedge Funds Weigh In On MiNK Therapeutics

A hedge fund recently raised its stake in MiNK Therapeutics stock. Renaissance Technologies LLC boosted its holdings in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 21.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 127,841 shares of the company’s stock after buying an additional 22,613 shares during the quarter. Renaissance Technologies LLC owned 0.37% of MiNK Therapeutics worth $121,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 2.87% of the company’s stock.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.